drugset / Trial / NCT02774564

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

NCT02774564

Phase 1 Completed 16 enrolled Bial - Portela C S.A.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa 200 mg/carbidopa 50 mg (Sinemet CR 200/50).

Timeline

Start
2005-09
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Levodopa Small molecule 200 mg
Subject Nebicapone Small molecule 50 mg Oral
Subject Nebicapone Small molecule 100 mg Oral
Subject Nebicapone Small molecule 200 mg Oral
Background Carbidopa Unknown 50 mg

Indications